I
n deoxycorticosterone (DOCA)-salt hypertension and other experimental models of hypertension, male rats develop an earlier and more severe form of hypertension than do female rats. [1] [2] We have recently suggested that differential activation of endothelin-1 (ET-1) pathways, expressed by a functional upregulation of ET B receptors, may play a role in the higher blood pressure (BP) levels observed in male DOCA-salt hypertensive rats. [3] [4] We observed that mesenteric arterioles from male but not female DOCA-salt rats display increased ET-1-and ET B -mediated responses and also that male DOCA-salt animals exhibit a marked and greater BP-lowering effect in response to bosentan, a mixed ET A /ET B antagonist, compared with that of female DOCA rats. [3] [4] Mechanisms underlying the attenuated alterations in the vascular ET-1 pathway in female DOCA-salt rats are unclear but may be related to the cardioprotective effects of ovarian hormones. Increasing evidence suggests that ovarian hormones suppress or modulate ET-1 production and its effects: (1) 17␤-estradiol attenuates ET-1-induced coronary artery constriction both in vitro 5 and in vivo 6 ; (2) plasma ET-1 levels fluctuate during the menstrual cycle 7 and are higher in men than in age-matched women 8 ; (3) ET-1 decreases during estrogen replacement therapy, during pregnancy (when estrogen levels are high), and during estrogen administration in transsexual male patients 8, 9 ; and (4) in the absence of ovarian hormones, ET-1 mRNA increases, as does the peptide. 10, 11 Therefore, the aim of the present study was to investigate whether the ovarian hormones modulate ET-1 vascular reactivity and expression in female DOCA-salt rats. We evaluated (1) responses to the ET B agonist Suc-[Glu, 9 Ala 11,15 ]-ET-1(8-21) (IRL-1620) in vivo/in situ in the mesenteric microcirculation, (2) the vascular mRNA expression of ET-1 and ET receptors, and (3) the BP-lowering effect of bosentan in female normotensive and DOCA-salt rats that were shamoperated, were ovariectomized, or received hormone replacement therapy following the ovariectomy.
Methods

Animals
Female Wistar rats from the Institute of Biomedical Science's animal facility were used in this study. All animals were fed standard laboratory rat chow, had ad libitum access to both food and water, and were housed individually in a room with a constant temperature (24°C) and a 12-hour/12-hour light/dark cycle. Experimental protocols followed standards and policies of the University of Sao Paulo's Animal Care and Use Committee.
Surgical Procedures
At 6 weeks of age, rats underwent ovariectomy under chloral hydrate anesthesia (300 mg/kg SC). Briefly, under aseptic conditions, a small incision was performed in the lower abdomen, and both ovaries were removed (OVX rats) or touched with the surgical instruments (sham). On the same day, some of these rats received pellets containing 17␤-estradiol (E; 0.1 mg/pellet; 60-day release; Innovative Research of America) or E plus progesterone (EP; 0.1 mg and 100 mg/pellet, respectively; 60-day release). Two weeks after surgery, these animals were randomized into 6 groups: (1) normotensive (control); (2) OVX normotensive (OVX-control); (3) OVXcontrol rats treated with E or EP (E-control or EP-control); (4) DOCA-salt rats (DOCA); (5) OVX DOCA-salt (OVX-DOCA); and (6) OVX-DOCA rats that received E or EP pellets (E-DOCA or EP-DOCA). DOCA-salt treatment, measurements of BP, and vascular reactivity, as well as assessment of hormone levels and effectiveness of ovariectomy and hormone replacement therapy, were performed as we previously reported. 3, 12 
Vascular mRNA Expression of ET-1 and ET A /ET B Receptors
Total cellular RNA was isolated from aorta/mesenteric arteries using TRizol reagent (GIBCO BRL, Life Technologies). After DNA digestion, total RNA (20 ng) was used for reverse transcription (RT) in the presence of a RNAase inhibitor, 200 U Moloney murine leukemia virus reverse transcriptase, and 1 g oligo(dT)12 to 18 primer at 37°C for 60 minutes. The cDNA products were isolated by phenol-chloroform extraction, precipitated by ethanol, and resuspended in 120 uL TE (10 mmol/L Tris-HCl, 1 mmol/L EDTA, pH 7.5). PCR primers were as follows: ET-1, antisense primer CTCGCTCTATGTAAGTCATGG and sense primer GCTCCT-GCTCCTCCTTGATG, which should amplify a 471-bp fragment; ET A , antisense primer CTGTGCTGCTCGCCCTTGTA and sense primer GAAGTCGTCCGTGGGCATCA (216-bp fragment); ET B , antisense primer CACGATGAGGACAATGAGAT and sense primer TTACAAGACAGCCAAAGACT (565 bp); and GAPDH, antisense primer CACCACCCTGTTGCTGTA and sense primer TATGATGACATCAAGAAGGTGG (219 bp). GAPDH was used as an internal control for the coamplification. The following conditions were selected for polymerase chain reaction (PCR) in a volume of 50 uL: RT products from 20 ng of RNA, 2.5 U Taq polymerase, 28 cycles of amplification for ET-1, 25 cycles for ET A /ET B receptors, and 20 cycles for GAPDH. After an initial denaturing cycle at 94°C for 5 minutes, the subsequent cycles were as follows: denaturation, 30 seconds at 94°C; annealing, 30 seconds at 55°C (ET-1, ET B ) or 60°C (ET A , GAPDH); and extension, 45 seconds at 72°C. PCR products (10 uL per lane) were electrophoresed by 1% agarose gel containing ethidium bromide 0.5 g/mL. The band intensities were measured using a software (Kodak Digital Science, Eastman Kodak Co), and the signals were expressed relatively to the intensity of the GAPDH amplicon in each coamplified sample.
Drugs
ET-1 and IRL-1620 were purchased from CalbiochemNovabiochem; DOCA and chloral hydrate were from Sigma Chemical Co. Bosentan was kindly provided by Dr Martine Clozel (Actelion Ltd, Allschwil, Switzerland).
Data Analysis and Statistical Evaluation
Values are expressed as meanϮSEM. Statistical evaluation of the data was performed by 2-way ANOVA followed by pair-wise multiple comparison procedures (Tukey Test) (SigmaStat, version 2.0, Jandel Scientific Software). PϽ0.05 was considered statistically significant.
Results
Ovariectomy accelerated the development and severity of hypertension in DOCA-salt rats (PϽ0.05). Hormone replacement, both with E or EP, restored BP levels in OVX-DOCA rats to values seen in DOCA rats (PϽ0.05). No differences were observed between the control, OVX-control and E-or EP-control groups. Systolic BP values are shown in the Table. Ovariectomized rats, both control and DOCA-salt rats, had significantly higher body weights than that of shamoperated rats, and the weight gain was reduced in the groups that received hormone treatment (PϽ0.05). To control for the efficacy of ovariectomy and hormone replacement, both the uterine weight and hormone plasma levels were evaluated. As can be observed in the Table, uterine body weight and plasma levels of E and EP were significantly reduced in the OVX groups and were restored with the hormone replacement therapy (PϽ0.05). Because responses in E-and EP-treated rats were similar at all protocols, only responses in the E-groups will be shown. (Figure 3 ). Mean arterial BP was higher in DOCA-salt rats compared with control rats (PϽ0.05). Bosentan (10 mg/kg IV) slightly but significantly decreased BP in the control groups. The antagonist lowered BP in DOCA-salt hypertensive rats, but the decrease on BP was significantly greater in the OVX-DOCA group. In the E-DOCA group, the effects of bosentan were similar to those observed in the DOCA group.
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Discussion
Ovarian hormones are believed to posses cardiovascular protective effects, and they seem to play a role in the gender-related differences in the development of hypertension in experimental models. 1-2 Because ET-1 plays a role in the pathogenesis of DOCA-salt hypertension, [13] [14] [15] [16] [17] it is possible that the attenuated development of hypertension in female DOCA-salt rats may be related to a modulation exerted by the gonadal hormones on ET-1 effects on the cardiovascular system. [5] [6] [7] [8] [9] [10] [11] We have recently reported that in DOCA-salt hypertension, male rats display altered vascular and pressor responses to ET-1 and to the ET B agonist IRL-1620 and that these alterations are attenuated in female rats. 3, 4 We specu- lated that the differential and gender-related alterations in ET-1-mediated effects in DOCA-salt hypertension may be important in the higher blood pressure levels observed in male DOCA-salt hypertensive rats. 3 On the basis of these results and considering that ovarian hormones modulate ET-1 responses/production, [5] [6] [7] [8] [9] [10] [11] in the present study we tested the hypothesis that the ovarian hormones influence the attenuated changes in ET-1 actions observed in female DOCA-salt rats.
The major observation in this study is that removal of the ovaries and, consequently, a significant reduction in estradiol and progesterone levels worsens the changes in ET-1-induced effects observed in female DOCA-salt rats: it enhances IRL-1620 -stimulated vasoconstriction, it further increases ET-1 and ET B receptor mRNA expression, and it exacerbates the BP-lowering effect of bosentan. Moreover, the implant of extended release pellets containing E or EP, which restored plasma levels of the hormones and uterine weight, reversed these changes. These data further support an important role for estradiol and progesterone in these processes. Changes in ET B vascular reactivity and expression have been observed in vessels from DOCA-salt hypertensive rats by us and others, 3, 4, 15 and both functional and molecular up-or downregulation of ET A and ET B receptors have been described in arterial hypertension. 18, 19 Additionally, gender differences in human saphenous vein ET-1 receptor density, as well as in the ratio of ET A to ET B receptors, favoring vasodilator effects in women, have also been reported. 20 Mechanisms whereby estradiol and progesterone influence the ET-1 system have not been fully evaluated. However, there is evidence that estradiol influences vascular responses to ET-1 via receptor-dependent and -independent processes. 21, 22 It could also be speculated that estradiol differentially influences expression of endothelial ET B receptors that induce vasodilation and influences expression of vascular smooth muscle cell ET B receptors that are vasoconstrictory. We found increased mRNA expression of ET B receptors in DOCA-salt rats, which was associated with increased ET Bmediated vasoconstriction. Although we were unable to differentiate the cellular source of ET B receptors, the fact that IRL-1620 induced vasoconstriction suggests that ET B expression may be primarily on vascular smooth muscle cells. The fact that hormone replacement normalize these responses suggests an estrogenic/progesteronic-sensitive process. However, these aspects still wait clarification. There is also the possibility that the changes in vascular responsiveness to ET B stimulation and ET-1/ET B receptor expression are secondary to differences in blood pressure rather than because of lack of the ovarian hormones. This is supported by studies that show that chronic increases in blood flow upregulate ET-1 receptors, including ET B receptors in arterial smooth muscle. 23 However, increased BP itself does not change ET-1 responses/production, because spontaneously hypertensive rats, which exhibit high BP, do not display alterations in the ET-1 pathway. 17 In conclusion, the present study demonstrates that the lack of ovarian hormones increases vascular mRNA expression of ET-1 and ET B receptor subtype as well as vasoconstrictor responses to IRL-1620 and the BP-lowering effects of bosentan, whereas hormone replacement with E or EP restores these responses to a pattern similar to that observed in female DOCA-salt rats. 
